Award
Missouri Veterans Commission BX-21-022
BLRD Research Career Scientist Award Application
Recipient
KANSAS CITY VA MEDICAL CENTER
Awarded
October 03, 2025
Identifier
BX-21-022
This award supports research to develop CCN5-based therapies for triple-negative breast cancer, focusing on molecular mechanisms and drug repurposing strategies to improve treatment outcomes for TNBC patients, funded by Veterans Affairs.
Description
The project involves developing and translating CCN5-based therapies for triple-negative breast cancer (TNBC). The project includes creating PEGylated CCN5 derivatives, developing drug repurposing strategies, and studying the molecular mechanisms of CCN5 in tumor suppression. The project is funded by the Veterans Affairs and is scheduled from October 1, 2025, to September 30, 2026. The project aims to identify therapeutic agents that inhibit TNBC growth and metastasis with minimal toxicity.